CSIMarket


Harpoon Therapeutics Inc   (HARP)
Other Ticker:  
 


 

Harpoon Therapeutics Inc

HARP's Financial Statements and Analysis



Harpoon Therapeutics Inc narrowed third quarter of 2023 net loss per share of $-0.46 compare to net loss per share of $-3.50 recorded in the same quarter a year ago a decrease from $0.30 eps realized in II. Quarter (Jun 30 2023).


third quarter of 2023
Earnings Per Share Revenues
$ -0.46 $  4 Mill
$+3.04     $-9M     -67.33 %



Harpoon Therapeutics Inc 's Revenue fell by -67.33 % in third quarter of 2023 (Sep 30 2023) year on year, to $4 million and declined by -78 % sequentially.


Harpoon Therapeutics Inc is

More on HARP's Income Statement



Harpoon Therapeutics Inc 's in thethird quarter of 2023 recorded net loss of $-1.802 million, an improvement compare to net loss of $-11.640 million in III. Quarter a year ago.

Sequentially company realized a net loss, compared to net income of $1.061 million in the previous quarter.

More on HARP's Growth

Harpoon Therapeutics Inc Inventories
In Sep 30 2023 company's net cash and cash equivalents decreased by $-16 million, capital expenditures grew by -0.65-86.00%, to $0 millions compare to same quarter a year ago

More on HARP's Cash flow Statement


Harpoon Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Harpoon Therapeutics Inc payed $ -18.98 cash per share, on a free-cash flow basis .

Book value grew by 45.69 % sequentially to $1.15 per share, -71.52% of net income per share in trailing twelve-month period were contributed to shareholder value.
Tangible Book value grew to $ 1.15 per share from $ 0.79.

Company issued 0.15 million shares or 3.97 % in Sep 30 2023.


More on HARP's Dividends

 Market Capitalization (Millions) 91
 Shares Outstanding (Millions) 4
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 33
 Net Income (TTM) (Millions $) 31
 Cash Flow (TTM) (Millions $) -53
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Harpoon Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Harpoon Therapeutics Inc had negative $ -18.98 cash flow per share, on a free-cash flow basis .

Book value grew by 45.69 % sequentially to $1.15 per share, -71.52% of net income per share in trailing twelve-month period were contributed to shareholder value.
Tangible Book value grew to $ 1.15 per share from $ 0.79.

Company issued 0.15 million shares or 3.97 % in Sep 30 2023.


More on HARP's Balance Sheets

 Market Capitalization (Millions) 91
 Shares Outstanding (Millions) 4
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 33
 Net Income (TTM) (Millions $) 31
 Cash Flow (TTM) (Millions $) -53
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Harpoon Therapeutics Inc Earnings

Harpoon Therapeutics Inc Reports Significant Improvement in Losses, Amidst Steep Decline in Revenue

Harpoon Therapeutics Inc (NASDAQ: HARP), a clinical-stage immunotherapy company, has recently announced its financial results for the most recent fiscal period. The company reported a loss of $-0.46 per share, which is a significant improvement compared to the loss of $-3.50 per share in the same period last year. Furthermore, the earnings per share (EPS) fell from $0.30 in the preceding quarter to the current level.
The revenue for Harpoon Therapeutics Inc fell sharply by -67.335% to $4.45 million in the mentioned period, compared to $13.62 million in the similar quarter a year prior. Sequentially, the revenue tumbled by -78.003% from $20.22 million. These revenue figures showcase the challenges the com...

Astonishing Growth: Harpoon Therapeutics Inc. Outperforms Industry Peers, with Record Revenue Improvement of 143.538% in Q2 2023

/>Harpoon Therapeutics Inc., a leading player in the Medical Equipment and Supplies industry, recently released its financial results for the second quarter of 2023. The company has displayed remarkable growth, recording a notable revenue improvement of 143.538% year on year, reaching $20.22 million. In addition, Harpoon Therapeutics Inc. has turned a profit, with earnings per share standing at $0.03. These positive financial outcomes have positioned the company favorably among its industry peers.
Financial Results Overview:
Harpoon Therapeutics Inc.'s revenues exhibited impressive growth, outperforming the majority of its Medical Equipment and Supplies industry counterparts. Comparing the second qua...

Harpoon Therapeutics Inc. Reports Impressive 45.327% Revenue Surge Amid Losses in Q1 2023

Harpoon Therapeutics Inc. is a biomedical company that lost money in the first quarter of 2023. The company reported a loss of $0.31 per share, despite a significant increase of 45.327% in revenue, which surged to $8.58 million from the similar financial reporting period a year ago. In contrast, the company realized no revenue in the preceding financial reporting period, and its share price was $1.29.
The company?s net deficit for the quarter ending March 31, 2023, was $-11.338 million, which is an improvement from the previous year's net loss of $-20.321 million for the same reporting period. It is a promising sign for the company that its loss has declined, signaling better control of expenses, and a m...


Date modified: 2023-11-12T11:15:06+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com